Noncompliance with directly observed therapy for tuberculosis: Epidemiology and effect on the outcome of treatment

Chest

Volumn 111, Issue 5, 1997, Pages 1168-1173

  Burman, William J ^a,b,d   Cohn, David L ^a,b   Rietmeijer, Cornelis A ^a,b   Judson, Franklyn N ^a,b   Sbarbaro, John A ^b,c   Reves, Randall R ^a,b  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d DENVER PUBLIC HEALTH   (United States)

Author keywords

adherence; alcoholism; directly observed therapy; homelessness; noncompliance; tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ALCOHOL ABUSE; ARTICLE; DRUG SENSITIVITY; FEMALE; HOMELESSNESS; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SPUTUM CULTURE; TREATMENT FAILURE; TUBERCULOSIS CONTROL; UNITED STATES;

EID: 0030917745     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.5.1168     Document Type: Article

References (26)

1. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144:745-49
2. Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest 1979; 76:741-43
3. Datta M, Radhamami MP, Selvaraj R, et al. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district programme. Tuber Lung Dis 1993; 74:180-86
4. Kok-Jensen A. The prognosis of pulmonary tuberculosis in patients with abuse of alcohol. Scand J Respir Dis 1970; 51:42-8
5. Ormerod LP, Prescott RJ. Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis. Respir Med 1991; 85:239-42
6. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179-84
7. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-32
8. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333:229-33
9. Fujiwara PI, Crawford PT, Woodley CL, et al. Drug-resistant tuberculosis in New York City, 1991-1994 [abstract]. Tuber Lung Dis 1995; 76:S97
10. Centers for Disease Control and Prevention. Tuberculosis morbidity - United States, 1995. MMWR 1996; 45:365-70
11. Cohn DL, Catlin BJ, Peterson KL, et al. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990; 112:407-15
12. Leviton A. Definitions of attributable risk. Am J Epidemiol 1973; 98:231
13. Edsall J. Collins JG, Gray JAC. The reactivation of tuberenlosis in New York City in 1967. Am Rev Respir Dis 1970; 102:725-36
14. Corcoran R. Compliance with chemotherapy for tuberculosis. Irish Med J 1986; 79:87-90
15. Ferrer X, Kirshbaum A, Toro J, et al. Compliance with tuberculosis treatment in adults in Santiago, Chile. Bol Oficina Sanit Panam 1991; 111:423-31
16. Simpson JM. Simple tests for the detection of urinary PAS. Tubercle 1956; 37:333-40
17. Fox W. The problem of self-administration of drugs: with particular reference to pulmonary tuberculosis. Tubercle 1958; 39:269-74
18. Sha K, Charles JM, Barringer S, et al. Prospective study of adverse drug effects during directly observed therapy (DOT) of tuberculosis [abstract]. Am J Respir Crit Care Med 1996; 153:A410
19. Etkind S, Boutotte J, Ford J, et al. Treating hard-to-treat tuberculosis patients in Massachusetts. Semin Respir Infect 1991; 6:273-82
20. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994; 330:1703-09
21. Burman WJ, Reves R, Stone B, et al. The molecular epidemiology of tuberculosis in Denver, Colorado: a 5-year study [abstract]. Am J Respir Crit Care Med 1995; 151:A555
22. Farmer P, Robin S, Ramilus SL, et al. Tuberculosis, poverty, and 'compliance:' lessons from rural Haiti. Semin Respir Infect 1991; 6:254-60
23. Centers for Disease Control and Prevention. Approaches to improving adherence to antituberculosis therapy - South Carolina and New York, 1986-1991. MMWR 1993; 42:74-81
24. Sbarbaro JA, Sbarbaro JB. Compliance and supervision of chemotherapy of tuberculosis. Semin Respir Infect 1994; 9:120-27
25. Hong Kong Chest Service / British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle 1979; 60:201-10
26. Hong Kong Chest Service / British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981; 1:171-74